| Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. | |
| | |
MedLine Citation:
|
PMID: 15569841 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Ghrelin is a novel growth hormone-releasing peptide that also induces vasodilation, inhibits sympathetic nerve activity, and stimulates feeding through growth hormone-independent mechanisms. We investigated the effects of ghrelin on left ventricular (LV) function, exercise capacity, and muscle wasting in patients with chronic heart failure (CHF). METHODS AND RESULTS: Human synthetic ghrelin (2 microg/kg twice a day) was intravenously administered to 10 patients with CHF for 3 weeks. Echocardiography, cardiopulmonary exercise testing, dual x-ray absorptiometry, and blood sampling were performed before and after ghrelin therapy. A single administration of ghrelin elicited a marked increase in serum GH (25-fold). Three-week administration of ghrelin resulted in a significant decrease in plasma norepinephrine (1132+/-188 to 655+/-134 pg/mL; P<0.001). Ghrelin increased LV ejection fraction (27+/-2% to 31+/-2%; P<0.05) in association with an increase in LV mass and a decrease in LV end-systolic volume. Treatment with ghrelin increased peak workload and peak oxygen consumption during exercise. Ghrelin improved muscle wasting, as indicated by increases in muscle strength and lean body mass. These parameters remained unchanged in 8 patients with CHF who did not receive ghrelin therapy. CONCLUSIONS: These preliminary results suggest that repeated administration of ghrelin improves LV function, exercise capacity, and muscle wasting in patients with CHF. |
| | |
Authors:
|
Noritoshi Nagaya; Junji Moriya; Yoshio Yasumura; Masaaki Uematsu; Fumiaki Ono; Wataru Shimizu; Kazuyuki Ueno; Masafumi Kitakaze; Kunio Miyatake; Kenji Kangawa |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2004-11-29 |
Journal Detail:
|
Title: Circulation Volume: 110 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2004 Dec |
Date Detail:
|
Created Date: 2004-12-14 Completed Date: 2005-05-25 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 3674-9 Citation Subset: AIM; IM |
Affiliation:
|
Department of Internal Medicine, National Cardiovascular Center, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan. nagayann@hsp.ncvc.go.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Body Weight / drug effects Cachexia / drug therapy*, etiology, physiopathology Chronic Disease Eating / drug effects Exercise* Female Ghrelin Heart Failure / complications, drug therapy*, physiopathology Hemodynamics Human Growth Hormone / blood Humans Infusions, Intravenous Male Middle Aged Oxygen Consumption / drug effects Peptide Hormones / administration & dosage, adverse effects, therapeutic use* Pulmonary Ventilation / drug effects Sympathetic Nervous System / drug effects, physiopathology Ventricular Function, Left / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Ghrelin; 0/Peptide Hormones; 12629-01-5/Human Growth Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibitio...
Next Document: Brachial artery vasodilator function and systemic inflammation in the Framingham Offspring Study.